Vistagen Therapeutics Inc (VTGN) 13F Positioning & Ownership Changes (Q2 2026)

VTGN ranks #5966 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

VTGN is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

54 institutions disclose a position in VTGN, but none treat it as a major bet — even Luminus Management LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Ken Griffin has trimmed its VTGN position for two straight quarters, cutting it by $511.1K while still holding $52.6K.

VTGN reported a net loss of $67.6M over the trailing twelve months.

• Not yet profitable — net loss of $67.6M over the trailing twelve months
• Revenue declined 120.5% year over year
• Net income declined year over year, from -$55.8M to -$67.6M
• Operating cash flow was negative, using $66.4M in cash
• Current ratio of 3.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.37x equity — within a conventional range